SCHEMBL3684485

SCHEMBL3684485

Cc1ccc(NC(=O)c2ccccc2C)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.79
SMN1; SMN2 Q16637 6/20 0.77
NPC1 O15118 8/20 0.72
RAB9A P51151 8/20 0.72
LMNA P02545 2/20 0.72
HTT P42858 2/20 0.72
TP53 P04637 1/20 0.72
NFKB1 P19838 1/20 0.72
NFKB2 Q00653 1/20 0.72
RELA Q04206 1/20 0.72
HSD17B10 Q99714 1/20 0.72
TYK2 P29597 1/20 0.70
FFAR1 O14842 1/20 0.67
MAPT P10636 5/20 0.65
THRB P10828 1/20 0.65
GAA P10253 4/20 0.63
ALDH1A1 P00352 3/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
TDP1 Q9NUW8 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519361 1.00 HPGD (0.79) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL7058035 0.90 RAB9A (0.79) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL21993 0.89 HPGD (1.00) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL11781486 0.87 HPGD (0.77) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL3468940 0.86 HPGD (0.74) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL14688750 0.86 NPC1 (0.63) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL19501494 0.86 HPGD (0.86) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL5038860 0.86 HPGD (0.74) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL2119568 0.86 HPGD (0.74) HPGDSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL679010 0.86 HPGD (0.74) HPGDSMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-62018289-A None JP disclosed
US-12497712-B2 Property modulation with chemical transformations REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-12-16 US disclosed
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-24 US disclosed
WO-2023061440-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI), INC. (CN) 2023-04-20 WO disclosed
US-20200370204-A1 PROPERTY MODULATION WITH CHEMICAL TRANSFORMATIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2020-11-26 US disclosed
US-20200370204-A1 PROPERTY MODULATION WITH CHEMICAL TRANSFORMATIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2020-11-26 US disclosed
CN-104193750-B Suppress mitotic Compounds and methods for by suppressing aurora kinase 千禧药品公司 2018-04-27 CN disclosed
US-9321766-B1 Kinase inhibitors ALLERGAN, INC. (US) 2016-04-26 US disclosed
US-8647528-B2 Water absorbing agent and production method thereof NIPPON SHOKUBAI CO., LTD. (JP) 2014-02-11 US disclosed
WO-2012129562-A2 COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS THE SCRIPPS RESEARCH INSTITUTE (US) 2012-09-27 WO disclosed
US-20080070124-A1 COMPOSITION FOR HOLOGRAPHIC RECORDING MEDIUM, HOLOGRAPHIC RECORDING MEDIUM, AND METHOD FOR PRODUCING THE SAME FUJIFILM CORPORATION (JP) 2008-03-20 US disclosed
CN-1287046-C Method for producing paper and yield-improving agent SEIKO PMC CORP (JP) 2006-11-29 CN disclosed
EP-1682181-A2 COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT Novartis AG (CH) 2006-07-26 EP disclosed
CN-1643215-A Method for producing paper and yield-improving agent SEIKO PMC CORP (JP) 2005-07-20 CN disclosed
WO-2005027972-A2 COMBINATION OF A VEGF RECEPTOR INHIBITOR WITH A CHEMOTHERAPEUTIC AGENT NOVARTIS AG (CH) 2005-03-31 WO disclosed
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed
EP-1129075-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS Novartis AG (CH) 2001-09-05 EP disclosed
WO-2000027820-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2000-05-18 WO disclosed
JP-S6218289-A THERMAL RECORDING MATERIAL MITSUI TOATSU CHEM INC 1987-01-27 JP disclosed
US-4123554-A Fungicidal and germicidal benzanilides KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1978-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250235543-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS DDB1, DCLRE1A, TP53BP1 HPGD 3546/4885SMN1; SMN2 2871/4885NPC1 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.